Brickell Biotech, Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own0.40% Shs Outstand119.38M Perf Week2964.38%
Market Cap546.42M Forward P/E- EPS next Y-0.19 Insider Trans0.00% Shs Float117.85M Perf Month2256.44%
Income-39.90M PEG- EPS next Q-0.05 Inst Own16.10% Short Float4.14% Perf Quarter1221.73%
Sales0.50M P/S1092.85 EPS this Y42.40% Inst Trans-9.77% Short Ratio0.53 Perf Half Y1351.22%
Book/sh0.13 P/B27.46 EPS next Y-5.00% ROA-153.70% Target Price1.08 Perf Year315.31%
Cash/sh0.11 P/C31.59 EPS next 5Y- ROE-191.60% 52W Range0.09 - 5.10 Perf YTD1459.63%
Dividend- P/FCF- EPS past 5Y39.90% ROI-160.00% 52W High-27.22% Beta0.23
Dividend %- Quick Ratio4.40 Sales past 5Y-51.20% Gross Margin- 52W Low3876.42% ATR0.39
Employees16 Current Ratio4.40 Sales Q/Q285.20% Oper. Margin- RSI (14)88.12 Volatility52.19% 20.46%
OptionableNo Debt/Eq0.00 EPS Q/Q46.50% Profit Margin- Rel Volume0.02 Prev Close3.57
ShortableYes LT Debt/Eq0.00 EarningsMay 12 AMC Payout- Avg Volume9.18M Price3.71
Recom1.50 SMA20644.81% SMA501078.04% SMA2001006.42% Volume12,218 Change3.92%
Aug-28-20Initiated Lake Street Buy $6
Aug-25-20Initiated Oppenheimer Outperform $5
Jul-06-22 08:00AM  
Jul-01-22 02:02PM  
May-19-22 08:00AM  
May-17-22 10:53AM  
May-12-22 04:01PM  
May-05-22 04:01PM  
May-04-22 10:53AM  
May-03-22 04:02PM  
Apr-30-22 08:50AM  
Apr-21-22 03:00PM  
Apr-19-22 09:53AM  
Mar-15-22 07:30AM  
Mar-10-22 08:00AM  
Mar-08-22 04:05PM  
Feb-02-22 07:30AM  
Nov-09-21 04:05PM  
Nov-01-21 04:05PM  
Oct-28-21 07:58AM  
Oct-27-21 04:32PM  
Oct-07-21 06:55AM  
Sep-17-21 08:00AM  
Sep-08-21 08:30AM  
Sep-01-21 07:05AM  
Aug-16-21 08:00AM  
Aug-12-21 04:01PM  
Aug-05-21 03:00PM  
Jul-29-21 08:00AM  
Jul-22-21 04:05PM  
Jul-19-21 10:44PM  
Jul-06-21 08:00AM  
Jun-30-21 04:12PM  
Jun-29-21 04:05PM  
Jun-24-21 08:00AM  
Jun-21-21 07:30AM  
Jun-01-21 08:00AM  
May-13-21 04:01PM  
May-06-21 03:00PM  
Apr-29-21 08:00AM  
Apr-27-21 07:30AM  
Apr-23-21 10:01AM  
Apr-16-21 10:00AM  
Apr-15-21 08:00AM  
Mar-09-21 04:01PM  
Mar-05-21 08:00AM  
Mar-02-21 12:30PM  
Feb-25-21 04:05PM  
Feb-23-21 04:01PM  
Jan-19-21 07:00AM  
Jan-06-21 12:50AM  
Dec-07-20 07:30AM  
Nov-18-20 07:00AM  
Nov-16-20 08:00AM  
Nov-12-20 04:01PM  
Oct-29-20 08:00AM  
Oct-22-20 08:00PM  
Sep-29-20 10:30AM  
Sep-25-20 07:00AM  
Sep-10-20 04:05PM  
Sep-08-20 07:30AM  
Aug-31-20 04:05PM  
Aug-12-20 04:01PM  
Aug-03-20 04:05PM  
Jun-17-20 10:00PM  
Jun-15-20 06:30AM  
May-31-20 08:04AM  
May-13-20 04:01PM  
May-04-20 04:05PM  
Mar-18-20 04:01PM  
Mar-09-20 04:05PM  
Mar-04-20 06:30AM  
Feb-20-20 11:43AM  
Feb-18-20 06:30AM  
Jan-10-20 04:05PM  
Nov-13-19 04:05PM  
Oct-30-19 04:42PM  
Sep-03-19 06:45AM  
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HARDY REGINALD LCHAIRMAN OF THE BOARDJul 26Buy0.67100,00067,420448,411Jul 27 04:43 PM
HARDY REGINALD LCHAIRMAN OF THE BOARDJul 23Buy0.66100,00066,230348,411Jul 27 04:43 PM
McAvoy David R.General Counsel and CCOJul 23Buy0.6718,12412,138128,879Jul 27 04:42 PM